Buprenorphine-naloxone microdosing
نویسندگان
چکیده
منابع مشابه
Buprenorphine, buprenorphine/naloxone and methadone maintenance: a cost-effectiveness analysis.
The use of heroin in Australia results in disproportionate harm. Although the evidence suggests that a relatively low proportion of the population aged 14 years and over have ever used (1.4%) heroin or have used it in the past 12 months (0.2%), heroin use remains a significant cause of death, injury, illness and social harm. Research demonstrates that being in treatment leads to less heroin use...
متن کاملPharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.
HIV-infected patients with opioid dependence often require opioid replacement therapy. Pharmacokinetic interactions between HIV therapy and opioid dependence treatment medications can occur. HIV-seronegative subjects stabilized on at least 3 weeks of buprenorphine/naloxone (BUP/NLX) therapy sequentially underwent baseline and steady-state pharmacokinetic evaluation of open-label, twice daily ti...
متن کاملPharmacology of the Buprenorphine/Naloxone Combination
In addition to buprenorphine monotherapy tablets, film and tablets combining 4 parts buprenorphine and 1 part naloxone (a mu opioid antagonist) are also being used in maintenance treatment for opioid dependence (Chiang and Hawks, 2003). (The original manufacturer of the combination tablets stopped supplying them but generic versions and new brand, Zubsolv®*, are now available.) In fact, the bup...
متن کاملPharmacology of the Buprenorphine/Naloxone Combination
In addition to buprenorphine monotherapy tablets, film and tablets combining 4 parts buprenorphine and 1 part naloxone (a mu opioid antagonist) are also being used in maintenance treatment for opioid dependence (Chiang and Hawks, 2003). (The original manufacturer of the combination tablets stopped supplying them but generic versions and new brand, Zubsolv®*, are now available.) In fact, the bup...
متن کاملBuprenorphine-naloxone therapy in pain management.
Buprenorphine-naloxone (bup/nal in 4:1 ratio; Suboxone; Reckitt Benckiser Pharmaceuticals Incorporation, Richmond, VA) is approved by the Food and Drug Administration for outpatient office-based addiction treatment. In the past few years, bup/nal has been increasingly prescribed off-label for chronic pain management. The current data suggest that bup/nal may provide pain relief in patients with...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Family Physician
سال: 2020
ISSN: 0008-350X,1715-5258
DOI: 10.46747/cfp.6612891